Burns – Pipeline Review, H1 2020 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Burns – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This latest Pharmaceutical and Healthcare disease pipeline provides an overview of the Burns (Dermatology) pipeline landscape.

A burn is damage to body’s tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers.

The Pharmaceutical and Healthcare latest pipeline guide Burns – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 4, 1, 19, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Burns (Dermatology).
• The pipeline guide reviews pipeline therapeutics for Burns (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Burns (Dermatology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Burns (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Burns (Dermatology)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Burns (Dermatology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Burns (Dermatology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
  

Key Topics Covered:

• Introduction
• Burns – Overview
• Burns – Therapeutics Development
• Burns – Therapeutics Assessment
• Burns – Companies Involved in Therapeutics Development
• Burns – Drug Profiles
• Burns – Dormant Projects
• Burns – Discontinued Products
• Burns – Product Development Milestones
• Appendix
  

Companies Mentioned

• AlgiPharma AS
• Alliance Pharma Plc
• Anterogen Co Ltd
• Bioharmony Therapeutics Inc
• Biomendics LLC
• CFM Pharma Holding BV
• Chrysalis BioTherapeutics Inc
• Combangio Inc
• Destiny Pharma Plc
• Energenesis Biomedical Co Ltd
• FirstString Research Inc
• FortuneRock (China) Ltd
• GNT Pharma Co Ltd
• Hunan Sanqing Pharmaceutical Co Ltd
• Hypo-Stream Ltd
• Madam Therapeutics BV
• Mallinckrodt Plc
• Marizyme Inc
• MediWound Ltd
• MicroCures Inc
• NeoMatrix Therapeutics Inc
• Novion Technologies Inc
• Phagelux Inc
• Riptide Bioscience Inc
• Se-cure Pharmaceuticals Ltd
• Shulov Innovative Science Ltd
• Stemsynergy Therapeutics Inc
• TGV-Inhalonix Inc
• Theragnostic Technologies Inc
• TreeFrog Therapeutics SAS
• USV Pvt Ltd
• viDA Therapeutics Inc
• Washburn Therapeutics Inc
  

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/iuwsyk

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900